OneSource Speci. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹17.6K Cr
Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth. OneSource Specialty Pharma expects continued strong revenue and EBITDA growth beyond FY28.
From OneSource Speci.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹1,515
Market Cap
₹17.6K Cr
Revenue Rank
Margin Rank
How does OneSource Speci. rank in Pharmaceuticals & Biotechnology?
Compare OneSource Speci. against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
OneSource Speci. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 1- →Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth.
- →Capacity expansions: New sterile lines coming online this quarter and end of FY27, tripling sterile days by FY28 to 675 days, enabling higher volumes.
- →Expansion in drug-device combination, biologics (including animal health and biosimilars), soft gelatin capsules, and injectables to drive growth beyond FY28.
- →Biologics contracts with large global players expected to contribute commercial revenues from FY29 onwards.
- →Soft gelatin capacity fully utilized with new greenfield facility planned to support growth.
- →Injectable business adding new capabilities (pre-filled syringes, lyophilization) to boost sales.
- →Addition of new customers enabled by increased capacity; supply constraints easing.
- →Revenue ramp-up expected from oncology soft gel NDA launch in current quarter, though near-term contribution small.
- →Overall sequential quarterly revenue and EBITDA growth expected through operating leverage from new capacity.
📈 Profitability & Margins
Rank 3- →OneSource Specialty Pharma expects continued strong revenue and EBITDA growth beyond FY28.
- →FY28 guidance: Organic revenue target of $400 million with EBITDA margins around 40%.
- →Sterile capacity expansions (three to four lines by FY28) will significantly increase sterile days, driving revenue uplift.
- →Biologics business, including partnerships with global biosimilar players, will contribute increasingly beyond FY28, with major commercialization from FY29 onwards.
- →Soft gelatin and injectable businesses expected to grow, supported by new capacity and new customer wins.
- →Opex has been front-loaded; optimal profitability to realize once all capacity is fully operational.
- →Long-term EBITDA trajectory remains upward, with growth driven by all modalities: drug device combination, biologics, soft gel, and injectables.
- →New product launches and customer additions also anticipated to sustain earnings growth.
- →No major capex expected this year outside existing plans; future expansions focused on biologics as demand visibility improves.
🏗️ Capital Expenditure Plans
Yes- →OneSource Specialty Pharma has committed approximately 80% of a planned US$100 million capex primarily for drug-device combination (DDC) capacity expansion.
- →No significant additional capex planned for the current year beyond the balance 20% of the $100 million.
- →Future biologics capacity expansion will require additional capex, but expected to be significantly lower than DDC investments.
- →New capacity additions for sterile injectable lines and lyophilization are underway, including a planned shutdown in H1 FY27 to expand injectable capacity.
- →Soft gelatin capacity expansion via a greenfield project is initiated due to current site capacity limits, with updates expected soon.
- →Investments focus on meeting strong order book demand and supporting FY28 objectives and growth beyond FY28 into FY29-30, including biologics mammalian and microbial capacity expansions.
💰 Fundraising & Capital Structure
No information- →As of the call on July 25, 2026, OneSource Specialty Pharma Limited has not indicated any immediate plans for significant new fundraising through debt or equity.
- →The company mentioned having made a capex investment of about US$100 million across sites, with around 80% already committed, mostly in drug-device combination.
- →For biologics capacity expansion, there may be future capex requirements, but these are expected to be significantly lower than current levels.
- →No significant additional capex beyond the committed amount is planned for this year.
- →The management is focused on using internal accruals and existing funds for capacity expansions and growth.
- →Any future need to add capacity, especially in biologics, could lead to further investment but no explicit announcements of fundraising were made during the call.
📋 Order Book & Pipeline
Yes- →The company has strong visibility on its order book and capacity utilization through FY27 and towards FY28.
- →Drug-device combination segment has very clear demand with customers in Canada, India, and emerging markets, supporting robust order book.
- →Biologics business shows significant traction with new contracts and a strong funnel expected to convert in coming quarters.
- →Soft gelatin and injectable businesses are filling capacity with new customers onboarding.
- →They have enough capacity to meet existing demand and plan new capacity additions from this quarter.
- →Overall, there is order book visibility supporting the company’s FY28 revenue guidance of $400 million.
- →The diverse customer base and multiple pillars reduce risk of temporary disruptions from individual customers.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What OneSource Specialty Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Hikal (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…
- Sigachi Indust. (Q1 FY27)
Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Key concall takeaways from…
- Gujarat Themis Biosyn Ltd (Q1 FY27)
Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth. Key concall takeaways from Gujarat Themis Biosyn Ltd's Q1 FY27…
- Fredun Pharma (Q1 FY27)
Long-term growth also supported by capacity expansion (INR30-40 crore CapEx per year) and planned acquisitions. Key concall takeaways from Fredun…
Frequently Asked Questions
What were OneSource Speci. Q1 FY27 results?
Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth. OneSource Specialty Pharma expects continued strong revenue and EBITDA growth beyond FY28.
What is OneSource Speci. share price analysis?
OneSource Speci. currently shows a strong growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹17,602 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Speci. planning capital expenditure?
OneSource Specialty Pharma has committed approximately 80% of a planned US$100 million capex primarily for drug-device combination (DDC) capacity expansion.
Keep OneSource Speci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.